Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients
- PMID: 30882234
- DOI: 10.1161/CIRCULATIONAHA.119.039818
Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients
Abstract
Background: Patients with end-stage renal disease who are undergoing dialysis are reported to be at high risk of sudden cardiac death (SCD), and to date, no therapy has been shown to be effective in reducing this risk. The feasibility and value of prophylactic implantable cardioverter-defibrillator (ICD) implantation to prevent SCD is uncertain.
Methods: We conducted the ICD2 trial (Implantable Cardioverter-Defibrillator in Dialysis Patients), a prospective, randomized, controlled study investigating the value and safety of ICD implantation to prevent SCD in 200 patients on dialysis with a left ventricular ejection fraction ≥35%, after adequate screening and optimization of other treatments. The primary end point was SCD. Secondary end points were all-cause mortality and ICD-related complications.
Results: The trial was stopped as per the recommendation of the data and safety monitoring board for futility reasons after inclusion of 188 patients, 97 in the ICD group and 91 in the control group. The median duration of follow-up was 6.8 years (interquartile range, 3.8-8.8 years). SCD occurred in 19 of 188 cases (10.1%), 11 of 97 in the ICD group and 8 of 91 in the control group. The cumulative SCD incidence at 5 years was 9.7% (95% CI, 3.3%-16.2%) in the ICD group and 7.9% (95% CI, 1.7-14.0%) in the control group, resulting in a hazard ratio of 1.32 (95% CI, 0.53-3.29; P=0.55). Overall, 99 of 188 patients died (52.7%), 52 in the ICD group and 47 in the control group. Five-year survival probability was 50.6% (95% CI, 39.8%-61.5%) in the ICD group and 54.5% (95% CI, 43.0-66.0%) in the control group, resulting in a hazard ratio of 1.02 (95% CI, 0.69-1.52; P=0.92). Among 80 patients who received an ICD, 25 adverse events related to ICD implantation occurred.
Conclusions: In a well-screened and well-treated population undergoing dialysis, prophylactic ICD therapy did not reduce the rate of SCD or all-cause mortality, which remained high.
Clinical trial registration: URL: http://www.controlled-trials.com . Unique identifier: ISRCTN20479861.
Keywords: dialysis; end-stage renal disease; implantable cardioverter-defibrillator; sudden cardiac death.
Comment in
-
Defibrillators Don't Deliver in Dialysis.Circulation. 2019 Jun 4;139(23):2639-2641. doi: 10.1161/CIRCULATIONAHA.119.040504. Epub 2019 Jun 3. Circulation. 2019. PMID: 31158000 No abstract available.
-
Implantable Defibrillators for Primary Prevention of Sudden Death in Patients on Dialysis.Am J Kidney Dis. 2019 Dec;74(6):857-860. doi: 10.1053/j.ajkd.2019.05.002. Epub 2019 Jun 27. Am J Kidney Dis. 2019. PMID: 31257051 No abstract available.
-
Letter by Simpson et al Regarding Article, "Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients".Circulation. 2019 Oct 29;140(18):e742-e743. doi: 10.1161/CIRCULATIONAHA.119.042788. Epub 2019 Oct 28. Circulation. 2019. PMID: 31657953 Free PMC article. No abstract available.
Similar articles
-
Outcome of Subcutaneous Implantable Cardioverter Defibrillator Implantation in Patients with End-Stage Renal Disease on Dialysis.J Cardiovasc Electrophysiol. 2015 Aug;26(8):900-904. doi: 10.1111/jce.12705. Epub 2015 Jun 16. J Cardiovasc Electrophysiol. 2015. PMID: 25952566
-
Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.Arch Cardiovasc Dis. 2018 Dec;111(12):758-765. doi: 10.1016/j.acvd.2018.05.004. Epub 2018 Aug 2. Arch Cardiovasc Dis. 2018. PMID: 30078651
-
Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.BMC Cardiovasc Disord. 2018 Mar 15;18(1):52. doi: 10.1186/s12872-018-0790-8. BMC Cardiovasc Disord. 2018. PMID: 29544442 Free PMC article.
-
Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.Cardiovasc Ther. 2017 Jun;35(3). doi: 10.1111/1755-5922.12253. Cardiovasc Ther. 2017. PMID: 28129469 Review.
-
Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis.Circ Heart Fail. 2012 Sep 1;5(5):552-9. doi: 10.1161/CIRCHEARTFAILURE.112.969626. Epub 2012 Jul 20. Circ Heart Fail. 2012. PMID: 22821634 Review.
Cited by
-
Subcutaneous versus Transvenous Implantable Cardioverter Defibrillator in Patients with End-Stage Renal Disease Requiring Dialysis: Extended Long-Term Retrospective Multicenter Follow-Up.J Pers Med. 2024 Aug 17;14(8):870. doi: 10.3390/jpm14080870. J Pers Med. 2024. PMID: 39202061 Free PMC article.
-
An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease.Rev Cardiovasc Med. 2024 Apr 11;25(4):144. doi: 10.31083/j.rcm2504144. eCollection 2024 Apr. Rev Cardiovasc Med. 2024. PMID: 39076544 Free PMC article. Review.
-
Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path.Rev Cardiovasc Med. 2024 Jun 25;25(6):232. doi: 10.31083/j.rcm2506232. eCollection 2024 Jun. Rev Cardiovasc Med. 2024. PMID: 39076321 Free PMC article. Review.
-
Management of patients with heart failure and chronic kidney disease.Heart Fail Rev. 2024 Sep;29(5):989-1023. doi: 10.1007/s10741-024-10415-9. Epub 2024 Jul 29. Heart Fail Rev. 2024. PMID: 39073666 Review.
-
Nutritional Strategies against Diabetic Nephropathy: Insights from Animal Studies and Human Trials.Nutrients. 2024 Jun 18;16(12):1918. doi: 10.3390/nu16121918. Nutrients. 2024. PMID: 38931271 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
